Wall Street Zen Upgrades Elanco Animal Health (NYSE:ELAN) to Buy

Wall Street Zen upgraded shares of Elanco Animal Health (NYSE:ELAN - Free Report) from a hold rating to a buy rating in a report published on Saturday morning.

ELAN has been the topic of a number of other reports. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of "Moderate Buy" and a consensus price target of $15.33.

Elanco Animal Health Trading Down 0.1%

Shares of NYSE ELAN traded down $0.02 during trading on Friday, reaching $14.62. The company had a trading volume of 806,807 shares, compared to its average volume of 5,071,235. The company's fifty day moving average price is $12.93 and its 200-day moving average price is $11.59. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $15.78. The stock has a market cap of $7.26 billion, a P/E ratio of 19.74, a PEG ratio of 2.86 and a beta of 1.67. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The firm's revenue was down 1.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.34 EPS. As a group, research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ELAN. Allworth Financial LP raised its stake in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after purchasing an additional 2,090 shares during the last quarter. CoreCap Advisors LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $29,000. Parallel Advisors LLC raised its stake in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares during the last quarter. NBC Securities Inc. purchased a new stake in shares of Elanco Animal Health in the first quarter worth approximately $40,000. Finally, Jones Financial Companies Lllp raised its stake in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.